Every material Form 8-K AYTU BIOPHARMA, INC has filed with the SEC since May 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Aytu BioPharma reported fiscal 2026 fourth-quarter net revenue of $16.1 million, up 6.4% from $15.1 million a year earlier, and a net loss of less than $0.1 million, versus a $19.8 million loss in the prior-year quarter. For the full year, net revenue fell 13.3% to $57.6 million and the net loss widened to $14.3 million from $13.6 million, while Adjusted EBITDA was negative $3.7 million compared with $9.2 million, reflecting planned investments in the EXXUA launch.
Q4 fiscal 2026 net revenue was $16.1 million versus $15.1 million; EXXUA contributed $3.9 million and ADHD Portfolio revenue fell to $10.4 million from $13.1 million.
Full-year fiscal 2026 net revenue was $57.6 million versus $66.4 million, and full-year net loss was $14.3 million, or ($1.16) per share, versus $13.6 million, or ($2.16) per share.
Q4 Adjusted EBITDA was $0.5 million versus $2.0 million a year earlier; cash and cash equivalents were $26.3 million at June 30, 2026, compared with $31.0 million at June 30, 2025.
The company scheduled a conference call and webcast for September 22, 2026, at 4:30 p.m. Eastern time.
Aytu BioPharma and Lannett Company mutually agreed on June 23, 2026 to terminate their exclusive Metadate CD license agreement, except for provisions that survive under a new Termination Agreement. Aytu may keep selling existing inventory at its discretion but must continue royalty reports and payments until those sales cease. The filing reports Metadate CD net revenue of $49,000 for the quarter ended March 31, 2026.
Termination effective June 23, 2026, by mutual agreement with Lannett Company, Inc.
Metadate Agreement dated May 11, 2022, amended July 6, 2023 and July 17, 2025, is terminated in its entirety apart from surviving provisions.
Aytu may sell existing inventory at its sole discretion and must keep providing royalty reports and paying royalties until sales cease.
Metadate CD net revenue was $49,000 for the quarter ended March 31, 2026.
Aytu BioPharma reported fiscal 2026 third-quarter net revenue of $12.4 million, down from $18.5 million a year earlier, and a net loss of $5.6 million, compared with net income of $4.0 million in the prior-year quarter. The company attributed the revenue decline mainly to lower ADHD Portfolio and Pediatric Portfolio sales as its marketing shifted toward the newly launched EXXUA, which contributed $2.4 million.
Net revenue was $12.4 million versus $18.5 million in Q3 fiscal 2025; ADHD Portfolio fell to $9.1 million from $15.4 million.
EXXUA net revenue was $2.4 million; the product was made commercially available in mid-December 2025 and formally launched in mid-January 2026.
Net loss was $5.6 million, or $0.53 per basic share, versus net income of $4.0 million, or $0.65 per basic share; the result includes a $1.3 million derivative warrant liability loss.
Adjusted EBITDA was $(2.8) million versus $3.9 million a year earlier; cash and cash equivalents were $26.7 million at March 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every AYTU BIOPHARMA, INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →